Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from AstraZeneca.

Medical Crossfire®: How Can We Maximize Immuno-Oncology Strategies in Small Cell Lung Cancers?

Release Date: June 30, 2020
Expiration Date: June 30, 2021

Activity Overview

This online, on-demand virtual symposium brings together renowned experts in lung cancer to provide a comprehensive update on the role of immuno-oncology (IO) in the management of patients with non–small cell lung cancer (SCLC). These thought leaders discuss a range of pertinent topics, including the biologic and clinical rational for IO therapy in SCLC, the role of checkpoint inhibitors in both newly-diagnosed extensive stage SCLC and subsequent lines of therapy. The panelists also investigate practical issues and safety concerns as well as future prospects of immunotherapy in SCLC.

This educational activity is an archive of a live virtual symposium held on June 19, 2020.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from AstraZeneca.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational program is directed toward the ASCO audience, primarily medical oncologists. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of cancer are also invited to participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Apply efficacy and safety data from recent trials with immunotherapy in patients with SCLC in multiple lines of therapy
  • Discuss strategies to mitigate and manage immune-related adverse events in patients with SCLC
  • Evaluate immunotherapeutic approaches in conjunction with combined modality therapy for patients with limited-stage SCLC
  • Assess biomarkers and techniques in development to optimize selection of patients with SCLC for immunotherapy

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.


Anne Chiang, MD, PhD
Anne Chiang, MD, PhD
Associate Professor of Medicine
Chief Network Officer
Deputy Chief Medical Officer
Smilow Cancer Care Network
Yale School of Medicine
New Haven, CT

Disclosures: Grant Research Support: AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb; Consultant: AstraZeneca; Other: Advisory board: AstraZeneca, Genentech/Roche, Jazz Pharmaceuticals.

Roy S. Herbst, MD, PhD
Roy S. Herbst, MD, PhD
Ensign Professor of Medicine (Medical Oncology) Professor of Pharmacology
Chief, Medical Oncology
Associate Director, Translational Research Yale Cancer Center
Yale School of Medicine
New Haven, CT

Disclosures: Grant Research Support: AstraZeneca, Eli Lilly and Company, Genentech/Roche, Merck & Co; Consultant: AbbVie, ARMO BioSciences, AstraZeneca, Biodesix, Bolt Biotherapeutics, Bristol Myers Squibb, Cybrexa, Eli Lilly and Company, EMD Serono, Genentech/Roche, Genmab, Halozyme, Heat Biologics, I-MAB Biopharma, Immunocore, Infinity Pharmaceuticals, Loxo Oncology, Merck & Co, Mirati Therapeutics, Nektar, Neon Therapeutics, NextCure, Novartis, Pfizer, Sanofi, Seattle Genetics, Shire plc, Spectrum Pharmaceuticals, Symphogen, Takeda, Tesaro, Tocagen; Other: Board member: Junshi Biosciences.

Leora Horn, MD, MSc
Leora Horn, MD, MSc
Associate Professor of Medicine
Assistant Vice Chairman, Faculty Development
Director, Thoracic Oncology Program
Vanderbilt University Medical Center
Nashville, TN

Disclosures: Grant Research Support: Boehringer Ingelheim, Bristol Myers Squibb, Xcovery; Consultant: Amgen, AstraZeneca, EMD Serono, Incyte, Merck, Pfizer, Roche-Genentech, Xcovery.

Charles M. Rudin, MD, PhD
Charles M. Rudin, MD, PhD
Chief, Thoracic Oncology Service
Codirector, Druckenmiller Center for Lung Cancer Research Sylvia Hassenfeld
Chair in Lung Cancer Research
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Consultant: Boehringer Ingelheim, Bristol Myers Squibb, Xcovery Amgen, AstraZeneca, EMD Serono, Incyte, Merck, Pfizer, Roche-Genentech, Xcovery.

The staff Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By